Avid Bioservices Inc (CDMO)

[goodJohnhunting]

innate and adaptive moiety..

The p3 trial proved the two ton elephant in the room. Thus the 30% data mining..

Anti Ps is not the issue. However as the data mining suggest, and what ive suggested the past 4 years, binding is.

Also, the fact that phosphatidylserine has endogenous cross reactive manifest properties, makes it targeted double jeopardy, so to speak..

Not to mention the issue of molelectrostatic bonding that B2GP1 initiates.. As you can see, and what is scientifically known about B2Gp1, its a crowded, cross reactive protein.. Lots of competition for a clumsy therapeutic, imo..

We miss Dr Thorpe's outside the box thinking!


All the best,
John